ASN-RASAGILINE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
03-05-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
RASAGILINE (RASAGILINE MESYLATE)
Fáanlegur frá:
ASCEND LABORATORIES LTD
ATC númer:
N04BD02
INN (Alþjóðlegt nafn):
RASAGILINE
Skammtar:
0.5MG
Lyfjaform:
TABLET
Samsetning:
RASAGILINE (RASAGILINE MESYLATE) 0.5MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MONOAMINE OXIDASE B INHIBITORS
Vörulýsing:
Active ingredient group (AIG) number: 0151662001; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2019-06-04
Vara einkenni
PRODUCT MONOGRAPH
Pr
ASN-RASAGILINE
RASAGILINE MESYLATE
0.5 MG AND 1 MG RASAGILINE TABLETS (AS RASAGILINE MESYLATE)
ANTIPARKINSON AGENT
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Preparation:
May 30, 2019
Control Number: 221339
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
.....................................................................................28
T
Lestu allt skjalið
